

1642 B

UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : MICHAEL VALENTINE AGREZ, ET AL.

Application No. : 10/019,816 Filed : March 27, 2002

Confirmation No. : 9944

For : METHOD OF MODULATING INTEGRIN MEDIATED CELLULAR

ACTIVITY AND AGENTS USEFUL FOR SAME

Examiner : Karen A. Canella

Attorney's Docket : ADAM-046XX (ORIGINALLY SW-046XX-AND FORMERLY BLAKE-046XX)

TC Art Unit: 1642

United States Postal Service as first class mail in an envelope

addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Sept. 28,2805.

By: HOOL day C. Her

Holliday C. Heine, Ph.D. Registration No. 34,346 Attorney for Applicant(s)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

It is desired to cite for the record in this application the enclosed references listed on the attached copy of PTO Form #1449. The paragraph(s) marked below are applicable to this Information Disclosure Statement.

[] (1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached Information Disclosure Statement is being filed within three months of the filing date of the above identified national application or within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 of the above identified application. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.

10/03/2005 MAHMED1 00000038 10019816

01 FC:1806

180.00 OP

-1-

WEINGARTEN, SCHURGIN, GAGNEBIN & LEBOVICI LLP TEL. (617) 542-2290 FAX. (617) 451-0313

Application No.: 10/019,816 Filed: March 27, 2002

TC Art Unit: 1642

Confirmation No.: 9944

[] (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.

- [] (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [X] (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
 - [] a statement under 37 CFR § 1.97(e); or
 - [X] the fee set forth in § 1.17(p) (check enclosed for \$180.00).

PETITION UNDER 37 CFR § 1.97(d)

[] (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(p).

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

[] (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(2)

[] (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of

Application No.: 10/019,816

Filed: March 27, 2002

TC Art Unit: 1642 Confirmation No.: 9944

information contained in the attached Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Where the status of the application has changed, unknown to the applicant, such that the boxes checked are no longer applicable, the Commissioner is authorized to accept this submission with any additional fees required by that change charged to Deposit Account No. 23-0804.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

Application No.: 10/019,816

Filed: March 27, 2002

TC Art Unit: 1642

Confirmation No.: 9944

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,

MICHAEL VALENTINE AGREZ, ET AL.

Holliday C. Heine, Ph.D.
Registration No. 34,346
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
Ten Post Office Square
Boston, Massachusetts 02109

Telephone: (617) 542-2290 Telecopier: (617) 451-0313

HCH/mc/326416-1 Enclosures

Date: September 28, 2005 Page 1 of 2

	The same of the sa		·					
U.S. DEPARTS FOR COMMERCE				ATTY. DOCKET NO.		APPLICATION NO.		
(REV. 05/03)	PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ADAM-046XX (originally SW-046XX; and formerly: BLAKE-046XX)				
						10/019,816		
	, ,	<i>37</i>		APPLICANT				
				Michael V	alentine Ag	grez, et al.		
				FILING DATE		TC ART UNIT		
				March 27,	2002	1642		
		U.S. PATENT I	DOCUMENT	rs .				
EXAMINER	DOCUMENT NUMBER	PUBLICATION/	NAME CI		CLASS	SUBCLASS FILING DA		DATE
INITIAL		ISSUE DATE						
	US 5,807,746	9/15/1998	Lin et al.					
	US 5,962,643	10/5/1999	Sheppard et al.					
	US 6,043,339	3/28/2000	Lin et al.					
	US 6,248,558	6/19/2001	Lin et al.					
	DOCUMENT NUMBER	DATE	CO	UNTRY	CLASS	SUBCLASS	TRANS YES	SLATIO NO
	WO 92/12236	7/23/1992	WIPO				х	
÷	WO 95/34295	12/21/1995	WIPO				Х	
	WO 98/16241	4/23/1998	WIPO				Х	
	OTHER DOCU	MENTS (including Au	uthor, Title, Do	ate, Pertinent Po	ages, etc.)			
	Liu, S. et al., "Binding of paxilling pp 676-681 (9 December 1999).	n to α₄ integrins mod	ifies integrin	-dependent bio	ological resp	oonses," Nature,	vol. 402	,
	Liu, X. et al., "Identified of a fun peptide analogs," Proc. Natl Acad					grin β ₃ by using	cell-perr	neable
-	Mainiero, F. et al., "The coupling proliferation," The EMBO Journal						eratinocy	rte
EXAMINER			DA	TE CONSIDE	RED			

3 SEP 3 0 2005 BE

Date: September 28, 2005

Page 2 of 2

U.S. DEBANGEMENT OF COMMERCE ATTY. DOCKET NO. APPLICATION NO. PATENT AND TRADEMARK OFFICE ADAM-046XX 10/019,816 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) APPLICANT: Michael Valentine Agrez, et al. FILING DATE TC ART UNIT March 27, 2002 1642 **U.S. PATENT DOCUMENTS EXAMINER** DOCUMENT NUMBER PUBLICATION/ **CLASS** SUBCLASS NAME FILING DATE INITIAL **ISSUE DATE** US 6,339,148 1/15/2002 Sheppard et al. US 6,432,680 8/13/2002 Lin et al. US 6,495,518 12/17/2002 Hawiger et al. Sheppard et al. US 6,576,432 6/10/2003 US 6,596,277 7/22/2003 Sheppard et al. US 6,639,056 10/28/2003 Sheppard et al. US 6,780,843 8/24/2004 Lin et al. US 6,787,322 9/7/2004 Sheppard et al. FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER **SUBCLASS** DATE COUNTRY **CLASS** TRANSLATION YES NO WO 99/49879 10/7/1999 **WIPO** X WO 01/37821 A1 **WIPO** 5/31/2001 X OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.) Sebolt-Leopold, J. et al., "Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo," Nature Medicine, vol. 5, no. 7, pp. 810-816 (July 1999). DATE CONSIDERED **EXAMINER** *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

HCH/mc/326411-1